Licensing · Southeast Asia · Announced 10 Nov 2025
Bio-Thera Solutions → Dr. Reddy's Laboratories
Bio-Thera granted Dr. Reddy's an exclusive licence to register and commercialise BAT2306, its secukinumab (Cosentyx) biosimilar, in nine Southeast Asian markets; Bio-Thera will develop, manufacture and supply.
Parties: Bio-Thera Solutions (China) → Dr. Reddy's Laboratories (India)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand, Vietnam
- Therapeutic area
- Immunology / Inflammation
- Asset
- secukinumab
- Announced
- 10 Nov 2025
Our analysis
Why this matters
On 10 November 2025 Bio-Thera Solutions announced an exclusive commercialisation and licence agreement with Dr. Reddy's Laboratories for BAT2306, its biosimilar to Novartis's Cosentyx (secukinumab). Dr. Reddy's is responsible for regulatory approvals and commercialisation in Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand and Vietnam. Bio-Thera develops, manufactures and supplies the product. Financial terms were not disclosed.
In October 2026 BAT2306 (Youzhuomei) became, by Bio-Thera's account, the first secukinumab biosimilar approved by any major regulator, with China's NMPA clearing it for psoriasis, ankylosing spondylitis and psoriatic arthritis. That approval strengthens the reference dossier partners can use in Southeast Asia.
The full analysis is free to read with a work email on this page.
Source: Pearce IP